[3H]‐Trimetazidine mitochondrial binding sites: regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance
- 1 June 2000
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 130 (3) , 655-663
- https://doi.org/10.1038/sj.bjp.0703348
Abstract
Trimetazidine, an antiischaemic drug, has been shown to restore impaired mitochondrial functions. Specific binding sites for [3H]‐trimetazidine have been previously detected in liver mitochondria. In the present study we confirm this observation and provide additional evidence for the involvement of these sites in the pharmacological effects of the drug. Inhibition experiments using a series of trimetazidine derivatives revealed the presence of three classes of binding sites. An N‐benzyl substituted analogue of trimetazidine exhibited a very high affinity (Ki=7 nM) for one of these classes of sites. Compounds from different pharmacological classes were evaluated for their ability to inhibit [3H]‐trimetazidine binding. Among the drugs tested pentazocine, ifenprodil, opipramol, perphenazine, haloperidol, and to a lower extent prenylamine, carbetapentane and dextromethorphan competed with high affinity, suggesting a similarity of high affinity [3H]‐trimetazidine sites with sigma receptors. [3H]‐Trimetazidine binding was modulated by pH. Neutral trimetazidine had about 10 fold higher affinity than protonated trimetazidine for its mitochondrial binding sites. Various cations also affected [3H]‐trimetazidine binding. Ca2+ was the most potent inhibitor and totally suppressed the binding of [3H]‐trimetazidine to the sites of medium affinity. An endogenous cytosolic ligand was able to displace [3H]‐trimetazidine from its binding sites. Its activity was not affected by boiling for 15 min, suggesting a non‐protein compound. These data suggest that mitochondrial [3H]‐trimetazidine binding sites could have a physiological relevance and be involved in the antiischaemic effects of the drug. British Journal of Pharmacology (2000) 130, 655–663; doi:10.1038/sj.bjp.0703348Keywords
This publication has 32 references indexed in Scilit:
- Trimetazidine: Experimental and Clinical Update ReviewCardiovascular Drug Reviews, 1998
- Evidence for the existence of [3H]‐trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition poreBritish Journal of Pharmacology, 1998
- Comparison of the effects of cyclosporine A and trimetazidine on Ca2+‐dependent mitochondrial swellingFundamental & Clinical Pharmacology, 1997
- The mitochondrial permeability transitionBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1995
- Does a radiolabelled ligand bind to a homogeneous population of non-interacting receptor sites?Trends in Pharmacological Sciences, 1995
- Effect of Trimetazidine on Mitochondrial Function and Oxidative Damage during Reperf usion of Ischemic Hγpertrophied Rat MyocardiumPharmacology, 1993
- A proposal for the classification of sigma binding sitesTrends in Pharmacological Sciences, 1992
- Haloperidol-sensitive (+)[3H]SKF-10,047 binding sites (σ sites) exhibit a unique distribution in rat brain subcellular fractionsEuropean Journal of Pharmacology: Molecular Pharmacology, 1990
- Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium propertiesLife Sciences, 1981
- Microelectrometric titration measurement of the pKa's and partition and drug distribution coefficients of narcotics and narcotic antagonists and their pH and temperature dependenceJournal of Medicinal Chemistry, 1975